Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Titel:
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Auteur:
Garcia-Campelo, Rosario Arrieta, Oscar Massuti, Bartomeu Rodriguez-Abreu, Delvys Granados, Ana Laura Ortega Majem, Margarita Vicente, David Lianes, Pilar Bosch-Barrera, Joaquim Insa, Amelia Dómine, Manuel Reguart, Noemí Guirado, María Sala, María Ángeles Vázquez-Estevez, Sergio Caro, Reyes Bernabé Drozdowskyj, Ana Verdú, Ana Karachaliou, Niki Molina-Vila, Miguel Angel Rosell, Rafael